ImClone cements Bristol alliance?
Executive Summary
Former Bristol-Myers Squibb VP-Financial Analysis Michael Howerton named ImClone VP-business development, a newly created position. The two companies recently completed a $2 bil. licensing agreement for ImClone's anticancer agent C225 (1"The Pink Sheet" Sept. 24, p. 20)
You may also be interested in...
Bristol Paying $2 Bil. For ImClone C225; New Milestone For Inlicensing Deals?
Bristol-Myers Squibb's $2 bil. investment in ImClone's anti-cancer monoclonal antibody C225 (cetuximab) represents a $500 mil. premium to the company's estimate of the peak annual sales potential for the agent.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials